Artios Pharma Announces the Start of First Clinical Study with the Dosing of its ATR Inhibitor, ART0380, to Patients - Arix Bioscience

Close Navigation

About Strategy Team Portfolio Insights Media Contact

Overlay

Artios Pharma Announces the Start of First Clinical Study with the Dosing of its ATR Inhibitor, ART0380, to Patients

11th February 2021

Portfolio

This post references, or is about Artios. Find out more by clicking below

Cambridge, UK

Useful Tools

Download, print or share this article

Print

Print Article Email

Email

Print

Stay Updated

Add your email below to stay updated with useful and informative content from Arix and our portfolio companies

Share Article